Novavax (NVAX) Publishes Results of United Kingdom Phase 3 Clinical Trial in NEJM, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
Go back to Novavax (NVAX) Publishes Results of United Kingdom Phase 3 Clinical Trial in NEJM, Demonstrating High Levels of Efficacy of COVID-19 Vaccine| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 3.96 -0.19 (4.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.15 | 52 Week High | $9.23 | |||
| Open | $4.09 | 52 Week Low | $1.16 | |||
| Day High | $4.12 | P/E | N/A | |||
| Day Low | $3.91 | EPS | $-0.30 | |||
| Volume | 1,588,218 | |||||
